What is the price of GBS Inc. (GBS)

The price of GBS Inc. (GBS) is $0.4732

What is the market cap of GBS Inc. (GBS)

The market cap of GBS Inc. (GBS) is $7.05M

GBS Inc. (GBS) P/B Ratio

Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Year	P/B Ratio	Change
Not enough data for the provided dates.

Year

P/B Ratio

Change

Not enough data for the provided dates.

Company	P/B Ratio	P/B Ratio Difference	Country
Abbott Laboratories ABT.US	3.7944	-	US
Stryker Corporation SYK.US	5.423	-	US
Medtronic plc MDT.US	2.0146	-	IE
Boston Scientific Corporation BSX.US	3.072	-	US
Edwards Lifesciences Corporation EW.US	4.9725	-	US

Company

P/B Ratio

P/B Ratio Difference

Country